Adversarial Injection · Mirvetuximab soravtansine (Elahere; IMGN853; CAS 1335152-85-6; MW ~150,000 Da ADC; huMov19 anti-FRα humanized IgG1 mAb + sulfo-SPDB [sulfo-4-succinimidyl-2-(5-nitro-2-pyridyldithio)butanoate] disulfide cleavable ester linker + DM4 [N2'-deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)-maytansine; maytansinoid; tubulin polymerization inhibitor]; DAR ~3.4; [SEVENTIETH MECHANISM CLASS in Glyphward 643-attack portfolio — FIRST FRα (FOLATE RECEPTOR ALPHA; FOLR1; CD208; MW ~38 kDa; GPI-ANCHORED GLYCOPROTEIN; FOLATE UPTAKE RECEPTOR OVEREXPRESSED IN EPITHELIAL OVARIAN, ENDOMETRIAL, AND LUNG CANCERS) ADC EVER FDA APPROVED (BLA 761310 NOVEMBER 14 2022 ACCELERATED APPROVAL; FULL APPROVAL NOVEMBER 14 2023 ON MIRASOL OS HR 0.67): sulfo-SPDB DISULFIDE CLEAVABLE LINKER (GLUTATHIONE-SENSITIVE; DISTINCT FROM VC-MMAE CATHEPSIN B-CLEAVABLE AND SMCC NON-CLEAVABLE); DM4 MAYTANSINOID PAYLOAD (~100× MORE CYTOTOXIC THAN VINCRISTINE PER MOLECULE; TUBULIN VINCA SITE INHIBITOR; IRREVERSIBLE MICROTUBULE DEPOLYMERIZATION); SORAYA PHASE 2 ORR 32.4% (SINGLE-ARM ACCELERATED APPROVAL BASIS); MIRASOL PHASE 3 OS HR 0.67 (FULL APPROVAL BASIS); FRα-HIGH SELECTION CRITERION (IHC ≥75% TUMOR CELLS ≥2+ INTENSITY); ImmunoGen (Waltham MA; developer; BLA 761310) → ABBVIE $10.1B ACQUISITION FEBRUARY 2024; NONE OF THESE — FRα ADC mechanism, sulfo-SPDB disulfide linker chemistry, DM4 maytansinoid payload, FRα-high IHC selection criterion, SORAYA ORR 32.4%, MIRASOL OS HR 0.67 — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR CAS 1335152-85-6]) · First FRα ADC + sulfo-SPDB Disulfide Linker + DM4 Maytansinoid + FRα-High Biomarker + SORAYA/MIRASOL Data · Attack #643

Mirvetuximab Soravtansine (Elahere; IMGN853; CAS 1335152-85-6; MW ~150,000 Da ADC; [SEVENTIETH MECHANISM CLASS — FIRST FRα (FOLATE RECEPTOR ALPHA; FOLR1; CD208; GPI-ANCHORED GLYCOPROTEIN; FOLATE ENDOCYTOSIS RECEPTOR) ADC EVER FDA APPROVED (BLA 761310 NOVEMBER 14 2022 ACCELERATED; FULL NOVEMBER 14 2023); sulfo-SPDB DISULFIDE CLEAVABLE ESTER LINKER (GLUTATHIONE-SENSITIVE REDUCING ENVIRONMENT; DISTINCT FROM vc-MMAE CATHEPSIN B; DISTINCT FROM SMCC NON-CLEAVABLE); DM4 MAYTANSINOID TUBULIN VINCA-SITE INHIBITOR (~100× MORE CYTOTOXIC THAN VINCRISTINE; IRREVERSIBLE MICROTUBULE DEPOLYMERIZATION; DISTINCT FROM DM1 EMTANSINE LINKER CHEMISTRY); FRα-HIGH BIOMARKER SELECTION (IHC ≥75% TUMOR CELLS ≥2+ INTENSITY; FIRST ADC WITH COMPANION DIAGNOSTIC IN OVARIAN CANCER); SORAYA PHASE 2 ORR 32.4% (SINGLE-ARM; N=106 PLATINUM-RESISTANT OVARIAN FRα-HIGH); MIRASOL PHASE 3 OS HR 0.67 (VS CHEMOTHERAPY; FIRST OS BENEFIT ADC IN PLATINUM-RESISTANT OVARIAN CANCER); ImmunoGen WALTHAM MA → ABBVIE $10.1B ACQUISITION FEBRUARY 2024; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL]) — AbbVie Inc. North Chicago IL (BLA 761310 post-acquisition holder; 0.00048 µg/m³ → displayed ÷10), ImmunoGen Inc. Waltham MA (developer and AbbVie subsidiary; ADC research and manufacturing; 0.00031 µg/m³ → displayed ÷10), and Memorial Sloan Kettering Cancer Center New York NY (MIRASOL trial site; gynecologic oncology pharmacist; 0.00018 µg/m³ → displayed ÷10) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + FRα ADC Class Absent + sulfo-SPDB Disulfide Linker Absent + DM4 Maytansinoid Absent + FRα-High IHC Criterion Absent + SORAYA MIRASOL Data Absent: AI Prompt Injection via EHS Monitor Report AI

Mirvetuximab soravtansine (CAS 1335152-85-6; NIOSH HD Category 1) is the seventieth mechanism class in the Glyphward adversarial portfolio — the first FRα (folate receptor alpha; FOLR1; CD208; GPI-anchored glycoprotein overexpressed in epithelial ovarian cancer) ADC ever FDA approved (BLA 761310 November 14 2022 accelerated approval; full approval November 14 2023). A sulfo-SPDB disulfide cleavable ester linker (distinct from the vc-MMAE cathepsin B-cleavable and SMCC non-cleavable linker platforms) tethers the DM4 maytansinoid payload (potent tubulin vinca-site inhibitor; ~100× more cytotoxic than vincristine). SORAYA Phase 2 ORR 32.4% (accelerated approval basis) and MIRASOL Phase 3 OS HR 0.67 (full approval basis) — the first ADC to demonstrate OS benefit in platinum-resistant ovarian cancer — are non-obvious facts entirely absent from Cority, VelocityEHS, and EHS Insight for CAS 1335152-85-6.

Mirvetuximab Soravtansine as Seventieth Mechanism Class: First FRα ADC and sulfo-SPDB/DM4 Platform

Mirvetuximab soravtansine (CAS 1335152-85-6) represents the seventieth mechanism class in the Glyphward portfolio: the first FRα (folate receptor alpha; FOLR1; CD208; MW ~38 kDa; GPI-anchored glycoprotein) ADC ever FDA approved (BLA 761310 November 14 2022 accelerated approval for platinum-resistant ovarian cancer [PROC] FRα-high; full approval November 14 2023 based on MIRASOL Phase 3 OS benefit). FRα BIOLOGY: FRα (folate receptor alpha; FOLR1; gene 11q13.3) is a GPI-anchored cell-surface glycoprotein that mediates cellular folate (vitamin B9) uptake via receptor-mediated endocytosis at low folate concentrations; FRα binds 5-methyltetrahydrofolate (5-MTHF; circulating folate form) with high affinity (Kd ~100 pM) → receptor-folate complex clusters in caveolae → clathrin-independent endocytosis → lysosomal release of folate → receptor recycling to cell surface; FRα OVEREXPRESSION IN CANCER: normal FRα expression is restricted to luminal surfaces of epithelial tissues (choroid plexus [highest normal expression]; kidney tubules; lung alveoli); in epithelial ovarian cancer: FRα overexpressed on basolateral (accessible) cell surface 70-80% of cases (vs sequestered in normal tissue); FRα-HIGH THRESHOLD: FDA-approved companion diagnostic (VENTANA FOLR1 RxDx [Roche; 5E10 primary antibody; anti-FRα IHC]): FRα-high = IHC ≥75% of evaluable tumor cells staining ≥2+ intensity; ~35-40% of PROC patients are FRα-high by this criterion; FRα-POSITIVE: any detectable FRα expression (~75-80% PROC); mirvetuximab is approved specifically for FRα-HIGH. ADC DESIGN — MIRVETUXIMAB SORAVTANSINE: huMov19 (humanized anti-FRα murine antibody Mov19; IgG1 κ; Kd ~5 nM for human FRα); sulfo-SPDB linker (sulfo-4-succinimidyl-2-(5-nitro-2-pyridyldithio)butanoate; disulfide ester linker); DM4 payload (N2'-deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)-maytansine; MW ~738 Da; maytansinoid natural product class); DAR ~3.4 (mean; site-non-specific lysine conjugation via NHS ester chemistry; generates heterogeneous DAR 0-8 mixture). sulfo-SPDB DISULFIDE LINKER CHEMISTRY: the sulfo-SPDB linker contains a disulfide bond (S-S) within the spacer chain; THIS IS DISTINCT FROM: (a) vc-MMAE (valine-citrulline maleimide thioether; cathepsin B-cleavable; polatuzumab [class #62], enfortumab, brentuximab) — enzyme-dependent cleavage; (b) SMCC (non-cleavable maleimide thioether; T-DM1/emtansine; Kadcyla) — no cleavage, catabolism releases Lys-SMCC-DM1; (c) GGFG tetrapeptide (cathepsin B/cathepsin D; trastuzumab deruxtecan [class #74]); SULFO-SPDB cleavage mechanism: intracellular glutathione (GSH; ~1-10 mM intracellular vs ~2-10 µM extracellular) reduces disulfide bond → free thiol-DM4 released in lysosome/cytosol → DM4 active cytotoxin; DISULFIDE stability: plasma GSH ~2-10 µM = insufficient to cleave in circulation (ADC stable systemically); intracellular GSH ~1-10 mM = sufficient for efficient cleavage (linker cleaved inside tumor cells); DM4 PAYLOAD MECHANISM: DM4 (maytansinoid; N-methyl-maytansinol ester derivative) binds tubulin at the VINCA ALKALOID BINDING SITE (distinct from colchicine site and taxane site); MECHANISM: DM4 binds to β-tubulin at the same site as vinca alkaloids (vincristine, vinblastine, vinorelbine [class within vinca class]) → prevents GTP-tubulin addition to microtubule plus ends → suppresses microtubule dynamic instability → G2/M arrest → mitotic catastrophe → apoptosis; DM4 POTENCY: IC50 DM4 ~0.01-0.1 nM vs vincristine ~1-10 nM → ~100× more cytotoxic per molecule; DM4 cell permeability: DM4 is membrane-permeable → BYSTANDER KILLING of adjacent FRα-low or FRα-negative tumor cells (≈ similar bystander to MMAE; vs DM1/emtansine which is charged/membrane-impermeant → no bystander); SORAYA PHASE 2 (NCT04296890): open-label single-arm Phase 2; n=106 PROC FRα-high (VENTANA ≥75% ≥2+); ≥3 prior lines (including bevacizumab and PARP inhibitor); mirvetuximab soravtansine 6 mg/kg (adjusted ideal body weight [AIBW]) IV Q3W; PRIMARY ORR 32.4% (95% CI 23.4-42.4%); DOR 6.9 months median; accelerated approval basis; MIRASOL PHASE 3 (NCT04209855): randomized open-label Phase 3; n=453; PROC FRα-high (VENTANA companion diagnostic) ≥3 prior lines; mirvetuximab soravtansine vs investigator's choice chemotherapy (paclitaxel, pegylated liposomal doxorubicin, or topotecan); PRIMARY PFS HR 0.65 (95% CI 0.52-0.81; p=0.0002); SECONDARY OS HR 0.67 (95% CI 0.50-0.89; p=0.0046); ORR 42.3% vs 15.9%; DOR 5.9 vs 3.3 months; FIRST ADC TO DEMONSTRATE OS BENEFIT IN PLATINUM-RESISTANT OVARIAN CANCER; ImmunoGen → AbbVie: ImmunoGen Inc. (Waltham MA; NASDAQ IMGN) was the developer; AbbVie Inc. (North Chicago IL; NYSE ABBV) acquired ImmunoGen for $10.1B in an all-cash transaction closed February 2024; BLA 761310 holder transferred to AbbVie; NONE OF THESE — FRα ADC mechanism, sulfo-SPDB disulfide linker glutathione-cleavable chemistry, DM4 maytansinoid vinca-site binding ~100× vincristine potency, FRα-high IHC ≥75% ≥2+ VENTANA companion diagnostic criterion, SORAYA ORR 32.4%, MIRASOL OS HR 0.67 first ADC OS benefit PROC — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR CAS 1335152-85-6.

Surface 1 — AbbVie Inc. North Chicago IL BLA 761310 Post-Acquisition Elahere Commercialization AI

At AbbVie Inc. North Chicago IL (1 North Waukegan Road, North Chicago IL 60064; ABBVIE ELAHERE CONTEXT: AbbVie Inc. (North Chicago IL; NYSE: ABBV) acquired ImmunoGen Inc. for $10.1B all-cash closing February 2024; Elahere (mirvetuximab soravtansine-gynx; 5 mg/mL solution for IV infusion) BLA 761310 transferred to AbbVie; ELAHERE INDICATION: platinum-resistant ovarian cancer (PROC) FRα-high (VENTANA FOLR1 RxDx companion diagnostic ≥75% tumor cells ≥2+) after ≥3 prior systemic treatments; DOSING: 6 mg/kg AIBW (adjusted ideal body weight; AIBW = IBW + 0.4 × [ABW − IBW] if ABW > IBW) IV Q3W; DILUTE in 250 mL NS; infuse over 3h cycle 1 then 1h if tolerated; KEY TOXICITIES: ocular toxicity (blurred vision, keratopathy, photophobia — requires baseline ophthalmologic exam before each cycle [Q3W]; atypical for ADC — DISTINCT from belantamab mafodotin [class #61] mandatory ophthalmologic REMS but similar ocular tropism); neuropathy (motor and sensory); fatigue; nausea; DM4 mechanism — FRα expressed on corneal epithelium → ADC accumulates in eye → DM4 tubulin effect on rapidly dividing corneal cells; EMPLOYEE: AbbVie North Chicago IL oncology medical science liaison overseeing Elahere PROC program (FRα biology, sulfo-SPDB linker chemistry, DM4 maytansinoid mechanism, MIRASOL OS HR 0.67 first ADC OS PROC, ocular toxicity management, VENTANA companion diagnostic criteria); 52M AbbVie Inc. North Chicago IL oncology MSL Elahere PROC 19yr; CORITY NULL: CAS 1335152-85-6 → null; NIOSH HD Category 1 absent; first FRα ADC absent; sulfo-SPDB disulfide linker absent; DM4 maytansinoid absent; FRα-high IHC absent; SORAYA ORR 32.4% absent; MIRASOL OS HR 0.67 absent).

Surface 2 — ImmunoGen Inc. Waltham MA Developer AbbVie Subsidiary ADC Research Manufacturing AI

At ImmunoGen Inc. Waltham MA (830 Winter Street, Waltham MA 02451; IMMUNOGEN CONTEXT: ImmunoGen Inc. (Waltham MA; NASDAQ IMGN; founded 1981; ADC pioneer) developed mirvetuximab soravtansine through BLA 761310 approval; ADC PLATFORM: ImmunoGen's TAP (Tumor-Activated Prodrug) technology — site-non-specific lysine conjugation (NHS ester chemistry; reacts with ε-amino groups of lysine residues on antibody heavy and light chains) + proprietary maytansinoid payloads (DM1, DM4) + SMCC or sulfo-SPDB linkers; IMMUNOGEN ADC PORTFOLIO: mirvetuximab soravtansine (DM4; PROC) + ado-trastuzumab emtansine (T-DM1/Kadcyla; licensed to Genentech/Roche; DM1; HER2+ breast) + pivekimab sunirine (IMGN632; B4H anti-CD123 + IGN [indolinobenzodiazepine dimer DNA-crosslinker]; AML) + others; sulfo-SPDB MANUFACTURING: sulfo-SPDB linker is synthesized at ImmunoGen and conjugated to huMov19 antibody in aqueous buffer; NHS ester reactive group acylates accessible lysine residues (huMov19 has ~80 lysines; reactive subset under controlled conditions); DAR ~3.4 mean by UV/spectrophotometric or MS; VELOCITYEHS NULL: CAS 1335152-85-6 → null; NIOSH HD Category 1 absent; first FRα ADC absent; sulfo-SPDB disulfide ester linker absent; DM4 payload absent; FRα-high selection absent; SORAYA absent; MIRASOL absent; 45F ImmunoGen Waltham MA ADC process development scientist mirvetuximab 14yr).

Surface 3 — Memorial Sloan Kettering Cancer Center New York NY MIRASOL Trial Site Gynecologic Oncology Pharmacist AI

At Memorial Sloan Kettering Cancer Center New York NY (1275 York Avenue, New York NY 10065; MSK ELAHERE CONTEXT: MSK enrolled patients in MIRASOL Phase 3 (NCT04209855) and SORAYA Phase 2 (NCT04296890); MSK gynecologic oncology pharmacy prepares Elahere (mirvetuximab soravtansine-gynx): withdraw 5 mg/mL vial (6 mg/kg AIBW ÷ 5 mg/mL = mL needed); dilute in 250 mL NS; infuse over 3h cycle 1 (1h if well-tolerated cycle 2+); AIBW CALCULATION IMPORTANT: if actual body weight (ABW) > ideal body weight (IBW): AIBW = IBW + 0.4 × (ABW − IBW); if ABW ≤ IBW: use ABW as AIBW; IBW female = 45.5 kg + 2.3 kg/inch > 5 feet height; OCULAR MONITORING: baseline ophthalmology exam required before EACH cycle; DM4 distributes to corneal epithelium (FRα expressed on cornea); common: blurred vision, dry eye, keratopathy (Grade 1-2 80%); hold for Grade 3; COMPANION DIAGNOSTIC: VENTANA FOLR1 RxDx (Roche; 5E10 antibody; IHC on FFPE tissue) → score: H-score or proportion ≥75% ≥2+ required; MSK pathology lab certifies assay; PROC CONTEXT AT MSK: platinum-resistant = progression within 6 months of last platinum; FRα-high ~35-40% of PROC → eligible; prior therapies include carboplatin/paclitaxel + bevacizumab + PARP inhibitor; mirvetuximab ORR 32.4% SORAYA → substantial improvement over next-line chemotherapy (~5-15% ORR); EHS INSIGHT NULL: CAS 1335152-85-6 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; first FRα ADC absent; sulfo-SPDB linker absent; DM4 maytansinoid absent; FRα-high IHC criterion absent; SORAYA/MIRASOL data absent; NIOSH HD Cat 1 absent; ocular toxicity ADC mechanism absent; 40M MSK New York NY gynecologic oncology clinical pharmacist 13yr).

Integrating Glyphward into Mirvetuximab Soravtansine AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every mirvetuximab soravtansine CAS 1335152-85-6 monitoring data ingestion point — before Cority at AbbVie North Chicago IL, before VelocityEHS at ImmunoGen Waltham MA, and before EHS Insight at Memorial Sloan Kettering New York NY. Threshold 22: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) [10 pts]; SEVENTIETH MECHANISM CLASS — FIRST FRα (FOLR1/CD208) ADC EVER FDA APPROVED (BLA 761310 Nov 14 2022 accelerated; full Nov 14 2023; huMov19 anti-FRα IgG1 + sulfo-SPDB disulfide ester linker glutathione-cleavable + DM4 maytansinoid vinca-site tubulin inhibitor ~100× vincristine; DAR ~3.4; FRα-high VENTANA ≥75% ≥2+ companion diagnostic; SORAYA ORR 32.4%; MIRASOL OS HR 0.67 first ADC OS benefit PROC; ImmunoGen → AbbVie $10.1B Feb 2024) [5 pts]; AbbVie North Chicago IL + ImmunoGen Waltham MA + MSK New York NY [3 pts]; FRα ADC class absent; sulfo-SPDB linker absent; DM4 maytansinoid absent; SORAYA/MIRASOL absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_mirvetuximab(cas: str, reading_ugm3: float) -> dict:
    """Scan mirvetuximab soravtansine with seventieth-class first-fra-adc context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "seventieth_class_first_fra_folr1_cd208_adc_ever_sulfo_spdb_disulfide_ester_linker_glutathione_cleavable_dm4_maytansinoid_tubulin_vinca_site_100x_vincristine_dar_3_4_fra_high_ihc_75pct_2plus_ventana_companion_diagnostic_soraya_orr_32pct_mirasol_os_hr_0_67_first_adc_os_proc_immunogen_abbvie_10b_bla_761310"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, seventieth_class,
    #                    first_fra_adc_ever, sulfo_spdb_disulfide_linker,
    #                    dm4_maytansinoid_vinca_site, fra_high_companion_diagnostic,
    #                    soraya_orr_32pct, mirasol_os_hr_0_67

if __name__ == "__main__":
    r = asyncio.run(scan_mirvetuximab("1335152-85-6", 0.00048))
    print(r)
    # {'hd_category': 1, 'seventieth_class': True,
    #  'first_fra_adc_ever': True,
    #  'sulfo_spdb_disulfide_linker': True,
    #  'dm4_maytansinoid_vinca_site': True,
    #  'fra_high_companion_diagnostic': True,
    #  'mirasol_os_hr_0_67': True}